WuXi AppTec co-led a round for Junshi and Yitai-backed Stemirna, which is putting the funding into development of an mRNA vaccine for covid-19.

China-based vaccine developer Stemirna Therapeutics has raised $200m in a funding round co-led by pharmaceutical group WuXi AppTec.

Financial services firm China Merchants Group’s Medical and Health Industry Equity Fund also co-led the round, with asset manager Greenwoods Asset Management and venture capital firm Sequoia Capital China.

Advantech Capital, China Reform Fund, Citic Securities, CMB International Capital, Forebright Capital, Kelly Yi Fang Capital, Orbimed and Tsing Song Capital were also among the participants.

Founded in 2016, Stemirna is working on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn